Bamlanivimab

Names

[ CAS No. ]:
2423943-37-5

[ Name ]:
Bamlanivimab

Biological Activity

[Description]:

Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab[1].

[Related Catalog]:

Research Areas >> Infection
Signaling Pathways >> Anti-infection >> SARS-CoV

[Target]

SARS-CoV-2[1]


[References]

[1]. Benschop RJ, et al. The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Sci Transl Med. 2022 Jul 27;14(655):eabn3041.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.